vTv Therapeutics (VTVT) Net Equity Issued and Repurchased (2018 - 2022)

vTv Therapeutics has disclosed Net Equity Issued and Repurchased across 5 years of filings, most recently posting -$5.0 million for Q4 2022.

• In Q4 2022, Net Equity Issued and Repurchased fell 880.19% year-over-year to -$5.0 million; the TTM figure through Dec 2024 stood at -$5.0 million (changed 0.0% YoY), while the FY2024 annual figure was $2.5 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased came in at -$5.0 million for Q4 2022 at vTv Therapeutics, down from $646000.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $17.0 million in Q3 2021 to a low of -$5.0 million in Q4 2022.
• Average Net Equity Issued and Repurchased over 5 years is $5.2 million, with a median of $5.4 million recorded in 2019.
• Year-over-year, Net Equity Issued and Repurchased soared 16876.74% in 2020 and sank 880.19% in 2022.
• Over 5 years, Net Equity Issued and Repurchased stood at $6.5 million in 2018, then plunged by 99.34% to $43000.0 in 2019, then surged by 10818.6% to $4.7 million in 2020, then plunged by 86.24% to $646000.0 in 2021, then slumped by 880.19% to -$5.0 million in 2022.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were -$5.0 million in Q4 2022, $646000.0 in Q4 2021, and $17.0 million in Q3 2021.